Cargando…

Curative surgery for multiple hepatocellular carcinomas after lenvatinib plus transarterial chemoembolization: a case report

Surgical therapy following lenvatinib (LEN) plus transarterial chemoembolization (TACE) is a useful therapeutic option for intermediate-stage hepatocellular carcinoma (HCC). A 66-year-old man with a history of hepatitis C was detected four masses in the caudate lobe and segment 6/7 of the liver, wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiraishi, Jin, Itoh, Shinji, Tomino, Takahiro, Yoshiya, Shohei, Nagao, Yoshihiro, Morita, Kazutoyo, Kayashima, Hiroto, Harada, Noboru, Ichiki, Yasunori, Yoshizumi, Tomoharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460836/ https://www.ncbi.nlm.nih.gov/pubmed/37645700 http://dx.doi.org/10.1093/jscr/rjad485

Ejemplares similares

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
por: Toshida, Katsuya, et al.
Publicado: (2022)

Association between Sarcopenia and Omega-3 Polyunsaturated Fatty Acid in Patients with Hepatocellular Carcinoma
por: Itoh, Shinji, et al.
Publicado: (2022)

Prevention of bile duct injury using indocyanine green fluorescence in laparoscopic liver cyst fenestration for giant liver cyst: a case report
por: Shimagaki, Tomonari, et al.
Publicado: (2022)

Elevation of Mac‐2 binding protein glycosylation isomer after hepatectomy is associated with post‐hepatectomy liver failure, total Pringle time, and renal dysfunction
por: Imai, Daisuke, et al.
Publicado: (2019)

Cancer‐associated fibroblasts promote tumor cell growth via miR‐493‐5p in intrahepatic cholangiocarcinoma
por: Toshida, Katsuya, et al.
Publicado: (2022)

Clinical effects of the use of the indocyanine green fluorescence imaging technique in laparoscopic partial liver resection
por: Itoh, Shinji, et al.
Publicado: (2022)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Caution for living donor liver transplantation with congenital portosystemic shunt: a case report
por: Nagao, Yoshihiro, et al.
Publicado: (2022)

Donor Skeletal Muscle Quality Affects Graft Mortality After Living Donor Liver Transplantation- A Single Center, Retrospective Study
por: Tomiyama, Takahiro, et al.
Publicado: (2022)

Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor‐4 inhibition in hepatocellular carcinoma
por: Iseda, Norifumi, et al.
Publicado: (2022)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Tachiiri, Tetsuya, et al.
Publicado: (2023)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma
por: Tomiyama, Takahiro, et al.
Publicado: (2022)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
por: Llovet, Josep M., et al.
Publicado: (2022)

A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
por: Tomiyama, Takahiro, et al.
Publicado: (2023)

Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria
por: Yonemura, Yusuke, et al.
Publicado: (2020)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
por: He, Ying, et al.
Publicado: (2023)

Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Li, Dailong, et al.
Publicado: (2023)

Adjuvant transarterial chemoembolization to improve the prognosis of hepatocellular carcinoma following curative resection
por: Kuang, Xuejun, et al.
Publicado: (2018)

Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
por: Jeon, Mi Young, et al.
Publicado: (2019)

Electrohydraulic lithotripsy and rendezvous nasal endoscopic cholangiography for common bile duct stone: A case report
por: Kimura, Koichi, et al.
Publicado: (2019)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
por: Wu, Juan, et al.
Publicado: (2023)

Which is better to use “body weight” or “standard liver weight”, for predicting small‐for‐size graft syndrome after living donor liver transplantation?
por: Toshima, Takeo, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Cai, Mingyue, et al.
Publicado: (2022)

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023)

Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization
por: Shi, Qin, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection
por: Jing, Chu-Yu, et al.
Publicado: (2017)

Transarterial chemoembolization of liver metastasis from renal cell carcinoma
por: Matsuda, Hiroto, et al.
Publicado: (2018)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Solitary fibrous tumor in the liver: case report and literature review
por: Yugawa, Kyohei, et al.
Publicado: (2019)

Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score–Matched Analysis
por: Chen, Yu-Xing, et al.
Publicado: (2022)

Pure laparoscopic hepatectomy in semiprone position for right hepatic major resection
por: Ikeda, Tetsuo, et al.
Publicado: (2012)

Retroperitoneal schwannoma preoperatively diagnosed as liver metastasis from colon cancer: A case report
por: Wang, Huanlin, et al.
Publicado: (2019)

Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
por: Baur, Johannes, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4c6c3hu4156oq4loa6a17uqls2